AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01899118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m2 d1
Study NCT01899118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 825mg/m2 bid d1-5/w,1-5w
Study NCT02391870 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBCT-PD
Description: Using an iterative process, the investigators modified MBCT to include a focus on perinatal depression (MBCT-PD). The modifications took into account developmental processes associated with the perinatal period, characteristics and correlates of perinatal depression, and the physical aspects of pregnancy.
Study NCT01036633 — intervention group
Intervention type: DEVICE
Intervention: Infrared Thermometer
Description: The infrared thermometer will be used to grade the severity of oral mucositis in patients undergoing antineoplastic chemotherapy for multiple myeloma. The photothermal camera will be used to take intraoral digital images of the mouth.
Study NCT00855322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gym exercise group intervention
Description: Gym based circuit class
Study NCT03107975 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human amniotic epithelial cells
Description: intrathecal injection of human amniotic epithelial cells
Study NCT02273908 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: The study is observational
Study NCT02325921 — intervention group
Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: One MRI examination, diagnostic scanning protocol as used for renal tumours with additional diffusion weighted sequences, but without contrast enhancement.
Study NCT04423575 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outpatient health care pathway
Description: A surgical procedure performed as an outpatient procedure means that the patient leaves the hospital before 8pm the same day. The surgery is identical but the standard care pathway is reinforced to insure a safe return to home.
Study NCT04085159 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antigen-specific T cells CART/CTL and DCvac
Description: Antigen-specific T cells CART/CTL and DCvac cells to treat cancer
Study NCT00956605 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer attention training systems for children with ADHD
Description: Computer attention training systems for children with ADHD, one with and one without EEG-biofeedback, were delivered via approximately 20 sessions to the participants
Study NCT00956605 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer attention training systems for children with ADHD
Description: Computer attention training systems for children with ADHD, one with and one without EEG-biofeedback, were delivered via approximately 20 sessions to the participants
Study NCT03721211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]Martinostat
Description: a type of dye used for radiographic imaging of the HDAC protein
Study NCT03721211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-PET scanner
Description: PET, or positron emission tomography, is a type of imaging test that uses a tracer, or dye, to make detailed pictures showing the activities of the cells that make up tissues and organs
Study NCT03346304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy (PDT)
Description: Photodynamic Therapy (PDT) using photosensitiser drug Fotolon
Study NCT05090306 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Routine ultrasound examination
Description: ULTRASOUND EXAMINATION Women recruited to take part in the study will undergo the routine ultrasound examinations and monitoring, including a fetal echocardiogram between 12-13+6 weeks of gestation (for the first trimester cases) and between 18-24 weeks of gestation (for the second trimester cases). Two-dimensional evaluation of each fetal heart will include a cine loop sweep obtained from the from the four-chamber view plane by moving the transducer cranially towards the upper mediastinum, allowing the visualization of the following planes: four-chamber view, left and right ventricular outflow tracts, three vessels and trachea view. The examination will be stored for further analysis.
Study NCT03731026 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LightPath® Imaging System and 68Ga-RM2
Description: Imaging System:The LightPath® Imaging System is an in vitro diagnostic device which has CE mark in Europe, in line with In Vitro Diagnostic Medical Devices 98/79/EC (post-marketing study).~Radiopharmaceutical: 68Ga-RM2 is an investigational Positron Emission Tomography (PET)/ Computed Tomography (CT) radiopharmaceutical.
Study NCT03731026 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 68Ga-RM2
Description: Radiopharmaceutical: 68Ga-RM2 is an investigational Positron Emission Tomography (PET)/ Computed Tomography (CT) radiopharmaceutical.
Study NCT03316066 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stellate ganglion block with ropivacaine 0.2% 5 mL
Description: Each patient will undergo two stellate ganglion blocks and receive both volumes of local anesthetics in random order. The stellate ganglion blocks will be separated by 3 weeks in order to assure that no residual effects from the previous block will influence the results.
Study NCT03316066 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stellate ganglion block wit ropivacaine 0.2% 2 mL
Description: Each patient will undergo two stellate ganglion blocks and receive both volumes of local anesthetics in random order. The stellate ganglion blocks will be separated by 3 weeks in order to assure that no residual effects from the previous block will influence the results.
Study NCT01691703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videolaryngoscope and Bonfils
Description: First, the Macintosh videolaryngoscope (Karl Storz, Tuttlingen, Germany) will be used to achieve the best possible view and space of the laryngeal inlet for the insertion and manoeuvring of the Bonfils® (Karl Storz, Tuttlingen, Germany). Once the anaesthesiologist considers the view achieved to be the best view possible, a picture will be taken using C-CAMTM for C-MAC (Karl Storz, Tuttlingen, Germany), not showing any part of the videolaryngoscope. Thereafter the Bonfils® intubation scope, which will be preloaded with the endotracheal tube, will be brought into position in front of the laryngeal inlet. Again a picture not showing any part of one of the two devices will be taken. Once the Bonfils® has entered the trachea, the tracheal tube will be placed in the correct position.
Study NCT03130140 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Macroscopic on-site evaluation
Description: Macroscopic on-site evaluation: any aspirated material on a glass slide for inspection of the presence of a macroscopic visible core (MVC). Length of MVC will be measured to determine the adequacy of that puncture.
Study NCT03130140 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Conventional EUS-FNA
Study NCT02612688 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACP Video Program
Description: The ACP Video Program consists of five videos that address ACP decisions: (1) General Goals of Care, (2) Goals of Care for Advanced Dementia, (3) Hospice, (4) Hospitalization, and (5) ACP for Healthy Patients. NH staff will offer videos to patients at these clinical triggers: (1) Within 7 days of admission or readmission; (2) Every 6 months for long-stay patients; (3) When there is a significant change in clinical status; (4) When a treatment decision arises for which there is a specific video; and (5) Special circumstances when goals of care are being considered (e.g., family visiting).
Study NCT00855322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrotherapy group exercise intervention
Description: Hydrotherapy group exercise class
Study NCT00855322 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control group
Description: No intervention
Study NCT01475032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 1535
Description: CHF 1535 (BDP/FF) for 12 weeks
Study NCT00567983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Restasis
Description: Restasis- (in the eye) Instill one drop twice daily Endura- (in the eye) Instill one drop twice daily
Study NCT00567983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Endura
Description: Restasis- (in the eye) Instill one drop twice daily Endura- (in the eye) Instill one drop twice daily
Study NCT02353871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: A solution containing 50 U in 0.25 mL (200 U/mL). Each vial contained 0.625 mL of deliverable volume of solution. A volume of 0.25 mL, containing 50 U of BTX-A-HAC NG (i.e. 10 U/0.05 mL) was withdrawn from the vial into a syringe for administration. The total treatment volume (0.25 mL) was divided into five injections (0.05 mL per injection), each of which was to be administered into predefined sites across the glabellar region (two injections into each corrugator muscle and one injection into the procerus muscle).
Study NCT02353871 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A solution containing only the excipients of BTX-A-HAC NG (identical in appearance to the active product). Each vial contained 0.625 mL of deliverable volume of solution. A volume of 0.25 mL was withdrawn from the vial into a syringe for administration. The total treatment volume (0.25 mL) was divided into five injections (0.05 mL per injection), each of which was to be administered into predefined sites across the glabellar region (two injections into each corrugator muscle and one injection into the procerus muscle).
Study NCT02108847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: .2% Ropivacaine
Study NCT02108847 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Study NCT02108847 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascia Iliaca Block
Description: Ultrasound-guided regional anesthesia block to the groin area.
Study NCT02108847 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Fascia Iliaca Block
Description: Ultrasound-guided regional anesthesia block to the groin area.
Study NCT00571896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Senna+ docusate
Description: Senna+Docusate: dose will be 8.6 mg senna concentrate with 50 mg docusate. The participants will take the medication as follows: 1. Drink 4-6 glasses of fluid a day for the first two weeks after surgery 2. Take 2 SennaS tabs at bedtime the first night home from the hospital 3. If no bowel movement that next morning, take 2 tabs after breakfast. 4. If no bowel movement by evening, take 3 tabs at bedtime 5. If no bowel movement that next morning, take 3 tabs after breakfast 6. Once you do have a bowel movement, use the regimen described in the step two steps prior to the last one you used as your daily regimen. So, if you had a BM the morning after 3 tabs at bedtime, use steps 2 \& 3 (2 tabs at night and in the morning) until the first-postoperative visit.
Study NCT00571896 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo pill: The participants will use the placebo pills in the following manner: 1. Drink 4-6 glasses of fluid a day for the first two weeks after surgery 2. Take 2 SennaS tabs at bedtime the first night home from the hospital 3. If no bowel movement that next morning, take 2 tabs after breakfast. 4. If no bowel movement by evening, take 3 tabs at bedtime 5. If no bowel movement that next morning, take 3 tabs after breakfast 6. Once you do have a bowel movement, use the regimen described in the step two steps prior to the last one you used as your daily regimen. So, if you had a BM the morning after 3 tabs at bedtime, use steps 2 \& 3 (2 tabs at night and in the morning) until the first-postoperative visit.
Study NCT04429035 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin K2
Description: Administration of 300 μg Vitamin K2 (MQ7) daily p.o
Study NCT04429035 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of 300 μg Vitamin K2 (MQ7) Placebo daily p.o
Study NCT01584518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Based on clinical standard per clinician
Study NCT03739255 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cacicol20
Description: Cacicol20 is supplied as a sterile single-dose solution of alpha 1-6 poly-carboxymethyl glucose sulfate One drop is instilled at each application to impregnate cornea.
Study NCT03739255 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ocluac is artificial tear which contains Hydroxypropylmethyl Cellulose and Sodium Chloride, It is presented in a 0.4 mL vial. One drop is delivered at each application.
Study NCT01263925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprostadil (Prostaglandin E1)
Description: 4-week Daily Treatment Period 1: 4 weeks of 1 x daily intravenous infusion of 3 ampoules (20 µg) of Prostaglandin E1 (total 60 µg) in 50 - 250 ml physiological saline solution over 2 hours.~4-week Interval Treatment Period 2: 4 weeks of 2 x weekly intravenous infusion of 3 ampoules (20 µg) of Prostaglandin E1 (total 60 µg) in 50 - 250 ml physiological saline solution over 2 hours.
Study NCT01263925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline
Description: 4-week Daily Treatment Period 1: 4 weeks of 2 x daily (including weekends) 600 mg Pentoxifylline tablets.~4-week Interval Treatment Period 2: 4 weeks of 2 x daily (including weekends) 600 mg Pentoxifylline tablets.
Study NCT01263925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Pentoxifylline oral
Description: 4-week Daily Treatment Period 1: 4 weeks of 2 x daily (including weekends) matching Placebo to Pentoxifylline tablets.~4-week Interval Treatment Period 2: 4 weeks of 2 x daily (including weekends) matching Placebo to Pentoxifylline tablets.
Study NCT01263925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Alprostadil (Prostaglandin E1) intravenous
Description: 4-week Daily Treatment Period 1: 4 weeks of 1 x daily intravenous infusion of Placebo in 50 - 250 ml physiological saline solution over 2 hours.~4-week Interval Treatment Period 2: 4 weeks of 2 x weekly intravenous infusion of Placebo in 50 - 250 ml physiological saline solution over 2 hours.
Study NCT02072421 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: PCI
Study NCT01888627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated care
Description: The IC model was implemented into a network of the Psychosis Center of the University hospital (UKE), private psychiatrists of the UKE catchment area and other outpatient facilities. Integrated Care involves ACT treatment within this network. Patients have access to all evidence-based interventions according to need.
Study NCT01965106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QPI-1007 Injection
Description: 1.5 mg QPI-1007 Injection
Study NCT01965106 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: (including placebo)
Description: Sham injection procedure
Study NCT03272711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg
Study NCT03272711 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive training program
Description: Online training program, 30 minutes a day, 5 times a week
Study NCT03272711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training program
Description: Online training program, 30 minutes a day, 5 times a week
Study NCT00903071 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Real PPL
Description: See above arm description
Study NCT00903071 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sim PPL
Description: See above arm description
Study NCT03482947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ultrasonography-guided TAP block
Description: (1 mL/kg of bupivacaine 0.25% plus 1 μ/kg dexmedetomidine).
Study NCT03482947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caudal epidural block
Description: (1 mL/kg of bupivacaine 0.25% plus 1 μ/kg dexmedetomidine)
Study NCT02379793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 80185 gel, vehicle, liquid paraffin
Description: Each subject has all 3 treatments applied at the same time. Each treatment is applied once to 2 locations on the subject.
Study NCT00698555 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine
Description: 5 different formulations, 2-dose intramuscular injection
Study NCT00698555 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: 3-dose intramuscular injection
Study NCT03420898 — intervention group
Intervention type: OTHER
Intervention: Quality Improvement Intervention, prescription reduction
Description: The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
Study NCT02828150 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition
Description: Patients will receive a tailored nutritional support (parenteral nutrition) to cover estimated protein-calorie requirements. Energy: resting energy expenditure \[Harris-Benedict\] multiplied by a factor of 1.5. Protein: 1.5 g/kg/day. In obese patients (BMI >30 kg/m2) support will be calculated on ideal body weight (BMI=23 kg/m2)
Study NCT04414631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conestat alfa
Description: Conestat alfa (8400 Units (U) followed by 4200 U every 8 hours, 9 administrations in total) will be administered as a slow intravenous injection (5-10 minutes) over a 72 hour period.
Study NCT04571697 — intervention group
Intervention type: DRUG
Intervention: Methotrexate
Description: No intervention or treatment will be administered as part of this study. Data of participants with first claim for a methotrexate in the patient's history are included.
Study NCT04571697 — intervention group
Intervention type: DRUG
Intervention: Anti-TNF
Description: No intervention or treatment will be administered as part of this study. Data of participants with first claim for an anti-TNF in the patient's history are included. Anti-TNF includes infliximab, golimumab, etanercept, certolizumab, and adalimumab.
Study NCT01482429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary weaning-ventilator protocol
Description: We implemented a multidisciplinary protocol for weaning from mechanical ventilation.This consist of a daily screening for readiness, performing a spontaneous breathing test, evaluation of signs of intolerance and decision on extubation.
Study NCT02759796 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Tailoring the flap according to clinical assessment
Description: After microvascular anastomosis is performed, the investigators clinically assess flap vascularization and the well vascularized tissue is marked by means of a dermographic pencil. Then the investigators administer 0,2mg/kg of ICG intravenously. The vascularization of the flap is also checked by means of the Photo Dynamic Eye (Pulsion Medical System) but finally the decision of discarding the poorly vascularized areas of the flap is made by clinical assessment.
Study NCT02759796 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tailoring the flap according to ICG Angiography assessment
Description: After microvascular anastomosis is performed, the investigators administer 0,2mg/kg of ICG intravenously. Then the investigators check the vascularization of the flap by means of the Photo Dynamic Eye (Pulsion Medical System) and the poorly vascularized areas of the flap are discarded guided by ICG perfusion test.
Study NCT02650466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nanopulse System
Description: The Nanopulse System consists of an electrical pulse generator, a handpiece, and a detachable applicator tip at the end of the handpiece that interfaces with the treatment area on the skin. The detachable applicator tip delivers the pulses to the skin through five 3 mm long needle electrodes (27 gauge). The applied electric field, is limited to the space enclosed by the 4 outer electrodes in the applicator tip. An inert, water based gel is applied to the skin and the applicator tip before making contact between subject and applicator tip to ensure that there are no air gaps present between the electrodes through which electrical arcing could occur while pulses are being delivered to the subject. The Applicator Tips are designed for single patient use, and are sterilized prior to first use and between treatment sessions using a standard steam autoclave.
Study NCT03492710 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunoglobulin
Description: Administer volume of IGIV-SN to maintain a trough level of of 5g/L or more
Study NCT01702870 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Study NCT00640198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: memantine
Description: Memantine was titrated in 5-mg weekly increments as recommended,from a starting dose of 5 mg/day to 20 mg/day. After the 3-week up-titration phase all patients received a fixed dose of either memantine (10 mg) or placebo twice daily without CIAT during the next 3 months (week 16). During the next 2 weeks (weeks 16-18), the drug treatment was combined with CIAT. This phase of combined treatment was followed by a 2-week period (weeks 18-20) where patients received memantine or placebo treatment alone and, finally, by a 4-week period of drug withdrawal (weeks 20-24)